Vanda Pharmaceuticals Inc (VNDA) reports strong Fanapt sales growth and strategic initiatives, despite facing increased ...

Kevin Moran; Chief Financial Officer, Senior Vice President, Treasurer; Vanda Pharmaceuticals Inc Mihael Polymeropoulos; Chairman of the Board, President, Chief Executive Officer; Vanda ...

M, consensus $284.9M Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and ...

Vanda Pharmaceuticals sees strong growth with Fanapt for bipolar I disorder, projects 2025 revenue up 6%-26%, and targets $1B by 2030.

For the psychiatry portfolio alone, Vanda is targeting annual revenue in excess of $750M in 2030, assuming the potential approval of Bysanti ...

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

WASHINGTON (AP) — WASHINGTON (AP) — Vanda Pharmaceuticals Inc. (VNDA) on Thursday reported a loss of $4.9 million in its fourth quarter. On a per-share basis, the Washington-based company said it had ...

H.C. Wainwright maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ:VNDA) with a price target of $18.00, representing significant upside potential from the current price of $4.31. According to ...

Vanda and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise imsidolimab to ...

Vanda Pharmaceuticals announced on Monday that the FDA had offered a hearing for the NDA of tradipitant, a neurokinin 1 (NK-1) receptor antagonist. This follows a period of contention after the ...

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.